A candidate nanoparticle vaccine comprised of multiple epitopes of the African swine fever virus elicits a robust immune response

The African swine fever (ASF) pandemics pose a significant threat to the global swine industry, and the development of safe and effective vaccines is a daunting but necessary challenge. The level and persistence of immunity are very important for the effectiveness of the vaccine. Targeting antigens...

Full description

Saved in:
Bibliographic Details
Published in:Journal of nanobiotechnology 2023-11, Vol.21 (1), p.424-424, Article 424
Main Authors: Song, Jinxing, Wang, Mengxiang, Zhou, Lei, Tian, Panpan, Sun, ZhuoYa, Sun, Junru, Wang, Xuannian, Zhuang, Guoqing, Jiang, Dawei, Wu, Yanan, Zhang, Gaiping
Format: Article
Language:English
Subjects:
African swine fever
African Swine Fever - prevention & control
African Swine Fever Virus
Animal vaccines
Animals
Antibodies
Antibody response
Antigen-presenting cells
Antigens
Bone marrow
Chemokine receptors
Epitopes
Epitopes, T-Lymphocyte
Ferritin
Fever
Hogs
Immune response
Immune system
Immunity
Immunogenicity
Industrial development
Lymphocytes
Lymphocytes T
NanoFVax
Nanoparticles
Nanovaccines
Pandemics
Peptides
Proteins
Robustness
Self-assembly
Swine
Vaccine candidate
Vaccines
Viruses
XCL1
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The African swine fever (ASF) pandemics pose a significant threat to the global swine industry, and the development of safe and effective vaccines is a daunting but necessary challenge. The level and persistence of immunity are very important for the effectiveness of the vaccine. Targeting antigens to antigen presenting cells (APCs) can greatly enhance immunogenicity. In this study, we developed a self-assembled nano-ASFV vaccine candidate (NanoFVax) targeting DCs, by covalently coupling the self-assembled 24-mer ferritin with the dominant B and T cell epitopes of the highly immunogenic ASFV antigen (p72, CD2v, pB602L and p30) and fused with the chemokine receptor XCL1 (a DC targeting molecule) through the SpyTag/SpyCatcher protein ligase system. Compared to monomeric protein, the nanoparticle vaccines can induce a more robust T-cell response, and the high-level antibody response against ASFV can last for more than 231 days. Therefore, the NanoFVax is a novel and promising vaccine candidate for ASFV.
ISSN:1477-3155
1477-3155
DOI:10.1186/s12951-023-02210-9